Azimuth Capital Investment Management’s Neurocrine Biosciences NBIX Stock Holding History

Azimuth Capital Investment Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$16M	Sell	121,704 -574	-0.5%	-$76.2K	0.6%	50
2025 Q4	$17.3M	Buy	122,278 +51,600	+73%	+$7.48M	0.62%	42
2025 Q3	$9.92M	Sell	70,678 -1,319	-2%	-$179K	0.36%	93
2025 Q2	$9.05M	Sell	71,997 -7,321	-9%	-$840K	0.34%	109
2025 Q1	$8.77M	Sell	79,318 -35,990	-31%	-$4.56M	0.35%	102
2024 Q4	$15.7M	Sell	115,308 -71	-0.1%	-$8.78K	0.61%	49
2024 Q3	$13.3M	Buy	115,379 +48,973	+74%	+$6.71M	0.52%	54
2024 Q2	$9.14M	Buy	66,406 +1,867	+3%	+$256K	0.37%	87
2024 Q1	$8.9M	Buy	+64,539	New	+$8.81M	0.37%	92

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Azimuth Capital Investment Management's NBIX Position: Q1 2026 in Review

Azimuth Capital Investment Management reduced its Neurocrine Biosciences (NBIX) stake by 0.47% in Q1 2026, selling an estimated $76.2K and leaving 121,704 shares worth $16M. The position accounts for 0.6% of the portfolio, ranked #50.

Azimuth Capital Investment Management first reported a position in NBIX in Q1 2024 and has held it in 9 quarters since. The position peaked at $17.3M in Q4 2025. 696 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

Azimuth Capital Investment Management held 121,704 shares of Neurocrine Biosciences worth $16M as of Q1 2026.
Azimuth Capital Investment Management sold 574 Neurocrine Biosciences shares in Q1 2026, an estimated $76.2K.
Neurocrine Biosciences made up 0.6% of Azimuth Capital Investment Management's portfolio in Q1 2026, its #50 holding.
Azimuth Capital Investment Management first reported a position in Neurocrine Biosciences in Q1 2024 and has held it in 9 quarters since.
Azimuth Capital Investment Management's Neurocrine Biosciences position peaked at $17.3M in Q4 2025.
696 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Azimuth Capital Investment Management's 13F filing for Q1 2026, filed 12 May 2026.